The efficacy and safety of atypical antipsychotics for the treatment of dementia: A meta-analysis of randomized placebo-controlled trials

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 915-937

  Ma, Hui ^a,b   Huang, Yinglin ^a   Cong, Zhengtu ^a   Wang, Yuan ^a   Jiang, Wenhai ^c   Gao, Shuhe ^c   Zhu, Gang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b YANSHAN UNIVERSITY   (China)

^c Daqing People's Hospital   (China)

Author keywords

Antipsychotic; clinical trial; dementia; meta analysis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

AGITATION; ARTICLE; BEHAVIOR; BRIEF PSYCHIATRIC RATING SCALE; CEREBROVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION OF CHANGE; CLINICAL GLOBAL IMPRESSION SCALE; COHEN MANSFIELD AGITATION INVENTORY; COMPARATIVE STUDY; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; INJURY; META ANALYSIS; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHIATRIC INVENTORY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SOMNOLENCE; URINARY TRACT INFECTION; BIBLIOGRAPHIC DATABASE; COMPLICATION; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; DATABASES, BIBLIOGRAPHIC; DEMENTIA; HUMANS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907141265     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140579     Document Type: Article

References (50)

1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E (2003) The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17, 63-67.
2. Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 25, CD003476.
3. Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A (2007) Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebocontrolled assessment of three fixed doses. Am J Geriatr Psychiatry 15, 918-931.
4. Kennedy J, DeberdtW, Siegal A,Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW(2005) Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry 20, 1020-1027.
5. Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A (2005) Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 13, 722-730.
6. Katz IR, JesteDV,Mintzer JE, Clyde C, Napolitano J, Brecher M (1999) Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 60, 107-115.
7. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F (2003) A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64, 134-143.
8. Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, Gharabawi G, Schneider LS (2006) Risperidone in the treatment of psychosis of Alzheimer disease: Results from a prospective clinical trial. Am J Geriatr Psychiatry 14, 280-291.
9. Street JS, ClarkWS,Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A (2000) Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57, 968-976.
10. Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH (2008) A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 16, 537-550.
11. Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C (2006) Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 14, 767-776.
12. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS (2009) Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: The CATIE-AD study. Am J Psychiatry 166, 583-590.
13. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. Am J Psychiatry 168, 831-839.
14. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A (2004) Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 19, 115-126.
15. De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, Iwamoto T (2005) Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study. J Clin Psychopharmacol 25, 463-467.
16. Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study, Group (2007) Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68, 1356-1363.
17. Paleacu D, Barak Y, Mirecky I, Mazeh D (2008) Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: A 6-week, doubleblind, placebo-controlled study. Int J Geriatr Psychiatry 23, 393-400.
18. Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: Metaanalysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14, 191-210.
19. Moher D, Jadad AR, Nichol G, Penman M,Tugwell P,Walsh S (1995) Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Control Clin Trials 16, 62-73.
20. Brown SA (1991) Measurement of quality of primary studies for meta-analysis. Nurs Res 40, 352-355.
21. Jadad AR1, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary Control Clin Trials 17, 1-12.
22. van Tulder M, Furlan A, Bombardier C, Bouter L, Editorial Board of the Cochrane Collaboration Back Review Group (2003) Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine (Phila Pa 1976) 28, 1290-1299.
23. Jüni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282, 1054-1060.
24. Cho HJ, Chung JH, Jo JK, Kang DH, Cho JM, Yoo TK, Lee SW (2013) Assessments of the quality of randomized controlled trials published in International Journal of Urology from 1994 to 2011. Int J Urol 20, 1212-1219.
25. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P (2003) Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 21, 192-198.
26. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CMJr, Feldman PD, Mintzer JE, Beckett LM, Breier A (2002) Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26, 494-504.
27. Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA (2009) A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc 10, 21-27.
28. Clark WS, Street JS, Feldman PD, BreierA(2001) The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 62, 34-40.
29. van Reekum R, Clarke D, Conn D, Herrmann N, Eryavec G, Cohen T, Ostrander L (2002) A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 14, 197-210.
30. Naber D, Greenspan A, Schreiner A (2007) Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): Results from a double-blind, randomized, placebo-controlled clinical trial. Psychopharmacology (Berl) 191, 1027-1029.
31. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R (2005) Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ 330, 874.
32. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA (2007) Quetiapine to treat agitation in dementia: A randomized, double-blind, placebo-controlled study. Curr Alzheimer Res 4, 81-93.
33. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA (1999) A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53, 946-955.
34. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, Study CATIE-AD, Group (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355, 1525-1538.
35. Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135.
36. Lyketsos CG, SteinbergM, Tschanz JT, Norton MC, Steffens DC, Breitner JC (2000) Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157, 708-714.
37. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 288, 1475-1483.
38. Sink KM, Holden KF, Yaffe K (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 293, 596-608.
39. Peuskens J, Rubio G, Schreiner A (2014) Dosing and switching of paliperidone ER in patients with schizophrenia: Recommendations for clinical practice. Ann Gen Psychiatry 13, 10.
40. Katz I, de Deyn PP,Mintzer J, Greenspan A, ZhuY, BrodatyH (2007) The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: A meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 22, 475-484.
41. Cheung G, Stapelberg J (2011) Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): A meta-analysis of randomised placebo-controlled trials. N Z Med J 124, 39-50.
42. Yury CA, Fisher JE (2007) Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom 76, 213-218.
43. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA 306, 1359-1369.
44. Jacobson NS, Truax P (1991) Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59, 12-19.
45. Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294, 1934-1943.
46. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, Gambassi G (2009) All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: A retrospective cohort study. J Clin Psychiatry 70, 1340-1347.
47. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169, 71-79.
48. Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, Saxton J, McDade E, Kamboh MI, DeKosky ST, Reynolds CF, 3rd, Klunk WE (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170, 1051-1058.
49. Fava GA(2006) The intellectual crisis of psychiatric research. Psychother Psychosom 75, 202-208.
50. Rosenthal R (1979) The file drawer problem and tolerance for null results. Psychol Bull 86, 638-641.